Working to bring peace of mind to the immunocompromised

Pro-Arc Diagnostics is a developing next-generation laboratory test for patients at risk of Progressive Multifocal Leukoencephalopathy (PML). PML is caused by the John Cunningham Virus and is responsible for thousands of deaths each year. To date, doctors have had no way to determine which patients were at risk for developing PML. Pro-Arc’s technology is being designed to identify these patients, which may eventually allow doctors to monitor PML risk and safely design treatment courses in response. Click here to learn more about JCV and PML.

Recent News

Dana Watt Selected to Join Springboard Enterprises Health Innovation Hub

Dana Watt, CSO of Pro-Arc Diagnostics, has been selected to participate in the 2017 batch of Springboard Enterprises’ Health Innovation Hub.

Dana joins 12 other women-led biotech and healthcare companies in a mentorship program designed to […]

Pro-Arc Diagnostics Wins 3rd Place in Accelerate STL Challenge

 

Pro-Arc Diagnostics placed 3rd in the 2016 Accelerate St. Louis Challenge, winning $20,000. Pro-Arc is thrilled to have the support of Accelerate St. Louis and the St. Louis community!

More details about Accelerate St. Louis, the […]

Pro-Arc Diagnostics Receives an Arch Grant

 

Pro-Arc Diagnostics is excited to announce it has been chosen to receive an Arch Grant as part of the Winter 2016 cohort! The team is thrilled to be working with the Arch Grants staff and […]

Pro-Arc Diagnostics awarded $25,000 Courageous Women Entrepreneurs Award from nCourage Entrepreneurs

 

The nCourage Entrepreneurs Investment Group awarded their $25,000 Courageous Women Entrepreneurs Award to Pro-Arc Diagnostics at the 2016 Rice Business Plan Competition (RBPC). Pro-Arc competed in the RBPC in Houston April 14th-16th and in addition to […]